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Abstract
Purpose Hyper-IgE syndrome (HIES) is a severe primary im-
munodeficiency, characterized by increased serum IgE levels
as well as recurrent infections and atopic dermatitis (AD)-like
skin lesions. AD is a chronic inflammatory skin disease with
immunologic alterations (Th2-Th22 polarization) and charac-
teristic skin barrier dysfunctions. Our aim was to investigate
physicochemical skin barrier alterations and allergic sensitiza-
tion in STAT3-HIES patients in order to explore whether skin
barrier dysfunction can play a role in the eczematoid skin
lesions in these patients.
Methods In our experiments STAT3 and FLG mutation anal-
yses were performed in STAT3-HIES (n=7) and AD (n=49)
patients. Laboratory parameters (LDH and Eos counts), im-
munologic alterations (Th17 cell counts), allergic sensitization
(total and specific IgE levels, skin prick tests, and medical
history records), skin barrier changes [transepidermal water
loss (TEWL), skin pH], serum and stratum corneum thymic
stromal lymphopoietin (TSLP) levels were also examined.
Results Impaired Th17 cell numbers, but normal physico-
chemical barrier functions, as well as serum and stratum
corneum TSLP levels, were found in STAT3-HIES, while
these parameters were significantly altered in AD patients.
Allergic sensitization was detected in nearly all AD patients,
while no signs of sensitization occurred in STAT3-HIES.
Conclusions Our study demonstrated that the skin barrier
functions of STAT3-HIES patients are not damaged and they
differ significantly from the altered skin barrier functions of
AD patients. Awell-functioning physicochemical skin barrier
may be one of the explanations on the contradiction between
the extremely high total IgE levels and the lack of allergic
sensitization in these patients. Our study underlines the impor-
tance of skin barrier in the development of allergic
sensitization.
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Introduction
Hyper IgE syndrome (HIES) is a rare, complex, primary im-
munodeficiency disorder with susceptibility to infections
caused by extracellular bacteria and fungi and also occurs with
atopic manifestations, such as extremely high serum IgE
levels and eczema [1]. It has been established that HIES is a
polysystemic disease in which not only the immune system is
aberrant, but skeletal and connective tissue abnormalities are
characteristic features [2]. Several investigations have re-
vealed that most patients with HIES have a dominant negative
mutation in the signal transducer and activator of transcription
3 (STAT3) gene, while in a minority of cases homozygous null
mutations in the dedicator of cytokinesis 8 (DOCK8), in phos-
phoglucomutase 3 (PGM3) genes cause autosomal recessive
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HIES associated with mycobacterial and viral infections
[3–7]. Although the underlying genetic defects are mostly
described in HIES, the knowledge of the molecular pathogen-
esis in the background of the clinical symptoms, including the
development of eczematoid skin lesions, which are often di-
agnosed as atopic dermatitis (AD)-like skin lesions, is limited
[8–10].
AD is a common chronic inflammatory skin disease that is
frequently accompanied by other atopic diseases such as al-
lergic rhinitis and bronchial asthma and is also associated with
elevated serum IgE levels [11]. Based on previous results,
immunological alterations and skin barrier dysfunctions are
indicated as important factors in the complex etiological back-
ground of AD [12]. Physicochemical skin barrier defects can
be the results of genetic mutations, such as the well-
characterized filaggrin (FLG) haploinsufficiency or copy
number variations, or can also be an acquired manifestation
that occurs after the harmful influence of several environmen-
tal agents [13]. This barrier impairment is a critical and early
factor in the development of inflammatory skin lesions in AD
and also a crucial event in allergic sensitization, which is a
characteristic feature of this disease [14].
In the present study our aim was to investigate for the first
time the physicochemical skin barrier alterations and allergic
sensitizations in STAT3-HIES patients in order to compare
them with those of AD patients and to find similar or different
pathogenetic events in the development of eczematoid skin
lesions in these two disorders. Importantly, we also intended
to strengthen the indirect connection between the physico-
chemical skin barrier and allergic sensitization.
Materials and Methods
Patients
Peripheral blood was obtained from 7 Caucasian patients with
STAT3-HIES, 3 males and 4 females (mean age: 16 years,
range: 4–40 years) and from 49 patients suffering from AD
with mild-to-moderate clinical symptoms. Patients with
STAT3-HIES and AD did not suffer from any concomitant
skin diseases at the time of the examination and had not been
treated with any moisturizers for 1 day, topical corticosteroids
or calcineurin inhibitors for 3 days, and with systemic immu-
nosuppressants for 28 days prior to examination. The follow-
ing biochemical parameters were examined on these two pop-
ulations: eosinophil count, serum lactate dehydrogenase
(LDH) level, total IgE and specific IgE levels (against house
dust mites, ragweed and cat dander antigens). Data on the
patients’ history of other allergic diseases and sensitization
were recorded. The severity of AD was determined using
OSCORAD (Objective SCORing Atopic Dermatitis). The lo-
cal skin inflammation of STAT3-HIES and AD skin lesions
was assessed by the TIS (Three Item Severity) scoring system.
Healthy controls (n=10) were included as the basis for the
comparison of barrier functions. All participants provided
written informed consent according to the principles of the
Declaration of Helsinki. The study was approved by the local
ethics committee.
Filaggrin and STAT3 Genotyping
Analysis of the most common FLG mutations R501X and
2282del4 was performed for all STAT3-HIES and AD pa-
tients, and STAT3 for STAT3-HIES patients. DNA isolated
from peripheral blood mononuclear cells with GenElute
Blood Genomic DNA Kit (Sigma, Chemical Co., St. Louis,
MO, USA) was subjected to polymerase chain reaction (PCR)
amplification. All PCR products were purified with QIAquick
PCR purification Kit (Qiagen, Inc) and bidirectionally se-
quenced on an ABI Prism 3100 automated sequencer with
Big-Dye terminator cycle sequencing reagents (Applied
Biosystems, Foster City, CA).
Evaluation of Intracellular IL-17 by Flow Cytometry
Measurement of IL-17 producing T cells was performed to
strengthen the diagnosis of STAT3-HIES patients as described
previously [15].
Measurement of Transepidermal Water Loss (TEWL)
and Skin pH
Measurements were performed under standardised laboratory
conditions at a temperature of 22–25 °C and a humidity level
of 40–60 %. Before the measurements, patients were allowed
to adapt to the room conditions for 5 min. TEWL measure-
ments (g/hm2) were carried out with Tewameter TM300
(Courage and Khazaka, Cologne, Germany) on nonlesional
(flexural forearm) and on lesional skin of patients. The dura-
tion of the measurements, performed in triplicates, was 30 s.
Skin pH measurements were carried out with pH 905 (Cour-
age and Khazaka, Cologne, Germany) on nonlesional (flexur-
al and extensor forearm), and lesional skin of patients. The
measurements were repeated 20 times, and the last value was
recorded, which was shown to be the steady state.
TSLP ELISA
Serumwas isolated from patients and aliquoted, and the TSLP
levels were determined using the ELISA Human TSLP
Quantikine Immunoassay according to the manufacturer’s in-
structions (R&D Systems, Minneapolis, MN).
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Measurement of the Stratum Corneum TSLP
Concentration
The tape-stripping method and measurement of the stratum
corneum TSLP expression level were carried out according
to the method described in a previous report by Sano et al.
[16].
Skin Prick Test
Skin prick test was performed with commercial test solutions
of ragweed, cat dander, house dust mite, peanut, milk, egg
white, and wheat (all from Lofarma S.p.A., Milan, Italy). Re-
action intensity was reported as described by manufacturer’s
instruction.
Statistical Analysis
To determine the statistical significance of the results, the
Kruskal-Wallis test and the Mann–Whitney test were used to
analyse nonparametric distributions, and Fisher’s exact test
was applied to compare specific IgE values and the history
of sensitization. P-values <0.05 were considered statistically
significant (*p<0.05; **p<0.01; ***p<0.005).
Results
Clinical and Immunological Characteristics
of STAT3-HIES Patients
In this study, we diagnosed 7 patients with STAT3-HIES on
the basis of National Institutes of Health-HIES (NIH-HIES)
score (Table 1), STAT3mutation analysis, IL-17 production of
T helper cells, and total IgE levels. All 7 patients showed
characteristic clinical and laboratory manifestation of
STAT3-HIES with the range of NIH scores between 44 and
70 points. The H332Y STAT3 mutation was detected in 3
patients, and the R382W STAT3 mutation was identified in
4 patients. The mean number of IL-17-producing Th17 was
significantly decreased in STAT3-HIES patients (0.12 % of
CD4+T cells) compared with healthy controls (0.99 % of
CD4+T cells). Total IgE levels were significantly higher in
patients with STAT3-HIES (mean: 8441 kU/L) compared to
healthy controls. In our AD patients, normal IL-17-producing
Th17 cell counts were measured (1.006 % of CD4+T cells),
but significant increases in mean total IgE levels were found
(mean: 3858 kU/L) (Table 2).
Skin Barrier Functions in STAT3-HIES and AD Patients
The TIS scoring system showed that the local severity of skin
lesions in STAT3-HIES and AD patients are comparable
(Table 2). None of the STAT3-HIES patients carried the two
most common FLG mutations (R501X and 2282del4), which
were present in 30.5 % of patients with AD. TEWL and skin
pH were measured on nonlesional skin of healthy controls as
well as of patients with STAT3-HIES and AD, and on lesional
skin of all patients. TEWL on nonlesional skin showed no
difference between the STAT3-HIES patients and healthy con-
trols, but the AD patients had significantly higher values
(Fig. 1a). On lesional skin, significant elevation in TEWL
was detected in the AD patients compared to the STAT3-
HIES group (Fig. 1b). Measuring pH on nonlesional skin,
the flexural forearm of STAT3-HIES patients showed signifi-
cant increase compared to healthy controls, but no signifi-
cance was detected on the extensor part. The pH of
nonlesional skin in the AD patient group showed significant
increases both on flexural and extensor parts compared to
healthy controls and STAT3-HIES patients (Fig. 1c–d). On
lesional skin, significant increase in pH were detected in AD
patients compared to STAT3-HIES patients (Fig. 1e).
Serum and Stratum Corneum TSLP Content
When determining serum and stratum corneum TSLP levels
in the three groups, no significant differences in serum and
stratum corneum TSLP levels were detected between the
STAT3-HIES patients and the healthy controls, but significant
increases were found in AD patients compared to the other
two groups (Fig. 2a–b).
Allergic Sensitization
Similarly to the barrier measurements, our data indicated that
the level of allergic sensitization differed profoundly between
AD and STAT3-HIES patients. AD patients showed signifi-
cantly elevated specific IgE levels against aeroallergens (cat
dander, ragweed and house dust mite) (Fig. 3a) compared to
the STAT3-HIES patient group, while no relevant specific IgE
level could be detected in the latter group. Skin prick test of
the STAT3-HIES patients displayed no positivity (data not
shown). In the personal medical history of the patients, the
occurrence of allergic asthma and rhinitis was observed sig-
nificantly higher in the AD group than in the STAT3-HIES
group (Fig. 3b).
Discussion
Cutaneous manifestations of STAT3-HIES are newborn rash,
Staphylococcus aureus-caused cold abscesses, mucocutane-
ous candidiasis and eczematoid lesions, which are often re-
ferred to as AD-like eruptions [17–19]. The eczema observed
in STAT3-HIES is similar to AD clinically (papular, pruritic
lesions with lichenification) and histopathologically, and both
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diseases are associated with eosinophilia and high serum IgE
levels, but there are also several distinctions. The skin involve-
ment in STAT3-HIES is mostly confined to the face and ex-
tensor surfaces of the extremities, while in AD, flexural sur-
faces are typically involved. Staphylococcal infections are
common in both diseases, but in AD they are usually superfi-
cial, whereas in STAT3-HIES cold abscesses may develop
[20]. Mucocutaneous candidiasis is a characteristic feature of
STAT3-HIES, but not that of AD. While high serum level of
allergen specific IgE is nearly absent in STAT3-HIES, AD is
often associated with severe sensitization and accompanied by
food allergy, asthma or allergic rhinitis [12]. In HIES the role
of Th17 cells is well-known, however, its contribution to the
development of eczematoid skin lesions remains unclear [21].
Table 1 NIH scoring system of STAT3-HIES patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Highest IgE (IU/ml) 10 10 10 10 10 10 10
Skin abscesses 8 8 2 4 4 4 0
Pneumonia 8 6 4 2 2 8 8
Lung parenchymal abnormality 0 0 0 0 0 0 6
Other serious infection 4 4 0 0 0 0 4
Fatal infection 0 0 0 0 0 0 0
Highest eosinophylia 0 0 0 0 3 0 0
Neborn rash 4 4 4 0 0 4 4
Eczema 4 2 2 4 4 2 0
Sinusitis/otitis (times/worst year) 4 4 2 0 0 1 4
Candidiasis 2 0 2 1 1 1 1
Retained primary teeth 2 0 2 2 2 2 0
Scoliosis/max curve 0 0 0 2 2 2 0
Pathologic fracture 8 0 0 0 0 0 0
Hyperextensibility 4 4 4 4 4 4 4
Characteristic face 5 5 5 5 5 5 5
Interalar distance 0 0 0 0 0 0 0
High palate 0 2 2 2 2 2 2
Midline anomaly 0 5 0 5 5 5 0
Lymphoma 4 0 0 0 0 0 0
Young age add-on at onset (AD) 7 7 7 5 5 5 7
Total 74 61 46 46 49 55 55
Table 2 Clinical parameters,
laboratory data (routine and
immunological), and mutations of
healthy controls (HC),
STAT3-HIES and AD patients
HC STAT3-HIES AD
Mean age with range (years) 28 (18–46) 16 (4–40) 19 (4–52)
Male/female ratio 5/5 3/4 22/27
Mean HIES SCORE N/A 44.28 N/A
Mean OSCORAD N/A 44.28 N/A
Mean TIS SCORE N/A 4.71 4.85
Mean Eosinophile count (Giga/L) 0.07 0.54 0.58
Mean LDH (U/L) 285.6 392.2 417.8
Mean Total IgE (kU/L) 98.4 8441 3858
Th17 cell numbers (%) 0.9933 0.1175 1.006
H332Y mutation in STAT3 gene 0 % (0/10) 42 % (3/7) N/A
R382W mutation in STAT3 gene 0 % (0/10) 58 % (4/7) N/A
R501X mutation in FLG gene 0 % (0/10) 0 % (0/7) 8.1 % (4/49)
2282del4 mutation in FLG gene 0 % (0/10) 0 % (0/7) 22.4 % (11/49)
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Since the eczematoid skin lesions of STAT3-HIES patients
are often diagnosed as AD-like skin lesions, and in AD pa-
tients cutaneous barrier alterations are considered to be ex-
tremely important in the development of skin inflammation
and allergic sensitization, our research group intended to
investigate these parameters also in STAT3-HIES patients in
order to explore whether physicochemical skin barrier dys-
function has a role in the pathogenesis of skin lesions in HIES.
On the basis of our results, skin barrier seems to function
normally in STAT3-HIES patients and does not play a
Fig. 1 Skin barrier functions of STAT3-HIES andAD patients. In TEWL
no difference was found between the STAT3-HIES patient group and
healthy controls on nonlesional skin, but the AD patients had
significantly higher values (P=0.0106 for STAT3-HIES and P=0.0152
for healthy controls) (Fig. 1a). Similarly, on lesional skin significant,
elevation in TEWL was observed in the AD patient group relative to
the STAT3-HIES patient group (P=0.0231) (Fig. 1b). Measuring skin
pH on flexural site of nonlesional skin, the STAT3-HIES patient group
showed significant increases compared to healthy controls (P=0.0238),
but not on extensor site. The pH of nonlesional skin in AD patient group
showed significant increase compared to healthy controls and STAT3-
HIES patients (P=0.0471 for STAT3-HIES and P<0.0001 for healthy
controls) (Fig. 1c–d). On lesional skin, significant increases in skin pH
were detected in AD patients compared to STAT3-HIES patients (P=
0.035) (Fig. 1e)
Fig. 2 Serum and stratum corneum (sc) TSLP levels of STAT3-HIES
and AD patients. Measuring serum and stratum corneum TSLP levels in
the three groups, no significant differences were detected between the
STAT3-HIES patients and the healthy controls, but significant increases
were observed in the AD patient group regarding both parameters when
compared to the other two groups (serum TSLP: P=0.0236 for healthy
controls and P=0.0329 for STAT3-HIES; stratum corneum TSLP: P=
0.020 for healthy controls and P=0.010 for STAT3-HIES) (Fig. 2a–b)
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significant role in the development ormaintenance of eczematoid
skin lesions. In our study, no differences in TEWL or in skin pH
were observed between healthy controls and STAT3-HIES pa-
tients, except in skin pH on the flexural nonlesional site of the
forearm, while significant differences were found between the
STAT3-HIES and AD groups for both nonlesional and lesional
skin areas. Moreover, no common filaggrin mutations were de-
tected in STAT3-HIES patients, which were present in 34.5 % of
our AD patients. Results showing serum and stratum corneum
TSLP levels also strengthened our hypothesis, since both were
significantly higher in AD group, when compared to healthy
controls and STAT3-HIES patients.
In the last few years, measuring TEWL has become one of
the most acceptable non-invasive method to examine physico-
chemical skin barrier alterations [22, 23]. Patients suffering
from AD, as well as transgenic mice with barrier gene defects
(e.g., CLDN1 and DSG3) show significantly elevated TEWL
compared to healthy controls [24, 25]. In these patients TEWL
measured on both lesional and nonlesional skin, showed strong
correlations with disease severity; however, during the physi-
cochemical skin barrier recovery this parameter decreased to a
normal level. Until now, no TEWL measurements have been
performed in STAT3-HIES patients with AD-like skin lesions.
Although skin pH plays a significant role in normal skin
barrier homeostasis, it is influenced not only by the barrier
functions, but also via numerous other factors (e.g., sweat
and sebum secretion, soaps) [26, 27]. AD skin shows a more
basic pH than normal skin, caused by the lower amount of
FLG breakdown products and the altered skin microbiome
[28]. Since it can be affected via the above-mentioned factors,
measuring skin pH is considered to be an indirect method to
detect skin barrier alterations. In our study, normal skin pH
was measured in STAT3-HIES patients, except on flexural site
of the forearm. This difference may be explained by the al-
tered skin microbiome of STAT3-HIES patients instead of
skin barrier disruption, since a recent study published that
the microbiome of these patients contain more Gram-
negative bacteria (especially Acinetobacter spp.), which may
alter the skin pH to basic [29].
One of the basic components of the physicochemical bar-
rier is FLG, which has a major role in crosslinking keratin
filaments [13, 30]. Moreover, its degradation products are
the natural moisturizing factors (NMFs) that buffer the pH
of the skin and have a role in UV protection (e.g., urocanic
acid), and immunomodulation [31]. In European AD patients,
basically five (R501X, 2282del4, S3247X, R2447X and
3702delG) FLG null mutations are predisposing to the dis-
ease, but in continental regions only R501X and 2282del4
are the most prevalent, which were detected in 34.5 % of
our AD patients [30]. Although only 7 STAT3-HIES patients
were investigated to these FLG mutations, the lack of these
major mutations suggests that FLG haploinsufficiency in the
molecular background of eczematoid skin lesions in these
patients, probably does not play as important role as it is in
AD patients.
However, the aforementioned methods (TEWL, skin pH,
FLG mutations) are well accepted to measure skin barrier
functions; the detection of serum and stratum corneum TSLP
levels are recently developed methods. Serum TSLP of AD
patients and mice with barrier disruption (FATP4 mutation)
showed significant increase of these parameters compared to
healthy controls, but the direct correlation between serum
TSLP levels and disease severity is still unclear [32–34]. A
recent investigation postulated that the stratum corneum TSLP
level was increased in AD patients, correlated with disease
severity (SCORAD), and the authors also suggested that stra-
tum corneum TSLP level could be used as a biomarker of
epidermal barrier status [16]. In our study, the serum and stra-
tum corneum TSLP levels were very similar in STAT3-HIES
patients compared to healthy controls, which data may also
suggest a well-functioning physicochemical skin barrier in
the disease and indicate the absence of AD-like skin
Fig. 3 Allergic sensitization. AD patients showed significantly elevated
specific IgE levels against aeroallergens (cat dander, ragweed and house
dust mite, P=0.0339 (Fig. 3a) compared to STAT3-HIES patient group,
where no relevant specific IgE levels could be detected. The occurrence
of allergic asthma and rhinitis in the personal medical history was
measured significantly less frequently in the STAT3-HIES group than in
the AD group (P=0.0023 for rhinitis and P=0.0030 for asthma) (Fig. 3b)
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inflammation; on the other hand in AD patients, these TSLP
levels were significantly higher compared to HIES patients
and healthy controls.
For a long time allergic diseases were considered primarily
to be the consequence of alterations in the adaptive immune
system (Th1-Th2 imbalance, missing immune deviation or
reduced immune suppression), but based on several recent
research data dysfunctional physicochemical barriers are
now recognized as critical elements in allergic sensitization
[35, 36]. FLG deficiency-mediated barrier disruption repre-
sents risk factor for sensitization in AD and contact dermatitis
patients. Other barrier-related gene defects may also predis-
pose to sensitization (SPINK5 – Netherton’s syndrome,
CDSN – Peeling skin syndrome) [37, 38].
In spite of the high IgE levels and the immunological alter-
ations, the development of allergic sensitization is not a char-
acteristic feature in STAT3-HIES patients, as it was detected
earlier and also in our present study [39]. In our study the
occurrence of allergic diseases (asthma, allergic rhinitis) dif-
fered significantly between the STAT3-HIES and AD groups.
In STAT3-HIES group no relevant specific IgE positivity or
clinically supported allergic sensitization were detected with
serum specific IgE measurement as well as with skin prick
test. Different mechanisms can stand in the background. In
STAT3-HIES patients defective IL-10 signalling in dendritic
cells has been detected, and since it is crucial for generating
inducible regulative T cells (Treg), it can result in inappropri-
ate Th2-Treg balance, in impaired T cell proliferation, in al-
tered suppression of cytokine production, and in higher IgE
levels and eosinophilia [40]. Another workgroup suggests that
compromised mast cell granulation and basophil activation
may play an important role in the prevention of allergic sen-
sitization development [41].We approached the question from
another side, whether well-functioning physicochemical bar-
riers can prevent sensitization in a disorder where immuno-
logical alterations would predispose to allergic diseases. We
suggest that the normal physicochemical skin barrier func-
tions, together with the above mentioned other mechanisms,
play role in the prevention of these patients from the develop-
ment of allergic sensitization, and this phenomenon can fur-
ther strengthen the significant connection between skin barrier
function and allergic sensitization.
Conclusion
In conclusion our study demonstrated for the first time that
skin barrier functions of STAT3-HIES patients are not dam-
aged, and are similar to those of healthy controls, as well as
differ significantly from the altered skin barrier functions of
AD patients. Since barrier defects are important in the patho-
genesis of AD skin lesions and seem to be missing in STAT3-
HIES, this may indicate different pathogenesis and may
explain the earlier detected clinical differences between the
eczematoid skin lesions in these two disorders. These findings
also suggest a distinct dermatological therapy for skin lesions
of STAT3-HIES patients from the usual AD therapies, since
barrier replacement therapies probably are not necessary. It
also raises the question whether the ‘AD-like skin lesions’
nomenclature is correct in STAT3-HIES.Moreover our results
provide a possible explanation why allergic sensitization is
missing or not common in STAT3-HIES patients, in spite of
their high serum IgE level and immunological alterations.
Furthermore, our investigation supplies additional data to sup-
port those findings that suggest a strong connection between
the skin barrier alterations and the development of allergic
sensitization. A limitation of this study is the relatively low
number of STAT3-HIES patients (since there are only 9 reg-
istered STAT3-HIES patients in Hungary), which indicates the
need for further investigations, but the significant results can
strengthen our main hypothesis.
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